The Work packages and deliverables of the NeuroBasic-PharmaPhenomics program warrant a considerable amount of new applications and technical products as well as an enormous development in knowledge.

These include

  1. novel screening tools that will lead to more refined and faster trials in the drug development process;
  2. new animal models, with genotypes representing models for neurological disease and endophenotypes of psychiatric diseases, which provide new valuable tools for the drug discovery process
  3. new drug classes with more direct effects and decreased side effects;
  4. new and improved hardware instruments for automated behavioral screening, including stimulus delivery and response measurement devices, and cage improvements;
  5. new and improved software for automated measurement of individual and social behavior, advanced data analysis and visualization, and distributed processing (grid computing);
  6. novel computational methods for complex data analysis needed to explore the multi-dimensional space of molecular to behavioral parameters.